FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 pts (24h)Health & MedicineOne-Off3m
KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Sí 98%+13.0pt
Calidad del mercado
47 / 100
Baja calidadVolumen 24h
480,1 €
Liquidez
1,3 mil €
Baja liquidezCompra / Venta
91.0% / 99.0%
Spread
8.0 pt
Spread amplioDatos de mercado
Actualizado hace 4 minutos
17 jun 26, 21:30 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketReglas
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida mediante:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Mercados abiertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 18,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 5,2 mil €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 resultados más
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volumen total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volumen total
- 916 mil €
- Volumen 24h
- 1,5 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 resultados más
- Volumen total
- 863,6 mil €
- Volumen 24h
- 1 mil €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi cotiza Yes al 98% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Está previsto que FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi liquida este mercado del siguiente modo: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.